Heron Therapeutics (HRTX) Long-Term Deferred Tax (2017)
Heron Therapeutics (HRTX) reported Long-Term Deferred Tax of $3.6 million for Q3 2017, little changed quarter-over-quarter from $3.6 million in Q2 2017.
Heron Therapeutics (HRTX) Long-Term Deferred Tax (2017) Analysis & Trends
Heron Therapeutics has reported Long-Term Deferred Tax for 1 years, with the latest figure at $3.6 million in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 3.60 Mn |
| Jun 30, 2017 | 3.60 Mn |
| Mar 31, 2017 | 3.60 Mn |